Abbott Laboratories (ABT) : Reliance Trust Co Of Delaware reduced its stake in Abbott Laboratories by 2.71% during the most recent quarter end. The investment management company now holds a total of 200,909 shares of Abbott Laboratories which is valued at $8,195,078 after selling 5,595 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Oct 14, 2016.Abbott Laboratories makes up approximately 0.75% of Reliance Trust Co Of Delaware’s portfolio.
Other Hedge Funds, Including , Duff Phelps Investment Management Co reduced its stake in ABT by selling 390 shares or 2.04% in the most recent quarter. The Hedge Fund company now holds 18,720 shares of ABT which is valued at $763,589. Abbott Laboratories makes up approx 0.01% of Duff Phelps Investment Management Co’s portfolio.Stokes Hubbell Capital Management boosted its stake in ABT in the latest quarter, The investment management firm added 679 additional shares and now holds a total of 46,058 shares of Abbott Laboratories which is valued at $1,979,112. Abbott Laboratories makes up approx 0.82% of Stokes Hubbell Capital Management’s portfolio.Hefty Wealth Partners boosted its stake in ABT in the latest quarter, The investment management firm added 616 additional shares and now holds a total of 704 shares of Abbott Laboratories which is valued at $30,089. Abbott Laboratories makes up approx 0.02% of Hefty Wealth Partners’s portfolio.Bath Savings Trust Co reduced its stake in ABT by selling 1,193 shares or 1.78% in the most recent quarter. The Hedge Fund company now holds 65,944 shares of ABT which is valued at $2,818,447. Abbott Laboratories makes up approx 0.89% of Bath Savings Trust Co’s portfolio.
Abbott Laboratories closed down -0.19 points or -0.46% at $40.79 with 88,18,965 shares getting traded on Friday. Post opening the session at $41.17, the shares hit an intraday low of $40.77 and an intraday high of $41.53 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.